The anthelmintic drug niclosamide and its analogues activate the Parkinson's disease associated protein kinase PINK1

Erica Barini, Ageo Miccoli, Federico Tinarelli, Katie Mulholland, Hachemi Kadri, Farhat Khanim, Laste Stojanovski, Kevin D. Read, Kerry Burness, Julian J. Blow, Youcef Mehellou, Miratul M. K. Muqit

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)


Mutations in PINK1, which impair its catalytic kinase activity, are causal for autosomal recessive early-onset Parkinson's disease (PD). Various studies have indicated that the activation of PINK1 could be a useful strategy in treating neurodegenerative diseases, such as PD. Herein, it is shown that the anthelmintic drug niclosamide and its analogues are capable of activating PINK1 in cells through the reversible impairment of the mitochondrial membrane potential. With these compounds, for the first time, it is demonstrated that the PINK1 pathway is active and detectable in primary neurons. These findings suggest that niclosamide and its analogues are robust compounds for the study of the PINK1 pathway and may hold promise as a therapeutic strategy in PD and related disorders.
Original languageEnglish
Pages (from-to)425-429
Number of pages5
Issue number5
Publication statusPublished - 2 Mar 2018


  • Drug discovery
  • Membranes
  • Mitochondria
  • Neurodegenerative diseases
  • Proteins

Cite this